Fifth Third Bancorp Common Stock vs NeoGenomics Inc. Common Stock — how do they compare? Fifth Third Bancorp Common Stock trades at $49.75 (market cap $45.54B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 21.3× NeoGenomics Inc. Common Stock's market cap, and Fifth Third Bancorp Common Stock pays a 3.35% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 6 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| FITB | NEO | |
|---|---|---|
Market Cap | $45.54B | $2.14B |
Volume | 4,742,681 | 2,228,400 |
Sector | Financials | Health |
52-Week High | $59.37 | $19.91 |
52-Week Low | $40.36 | $7.19 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $63.41B | $2.44B |
Dividend Yield | 3.35% | — |
Signals from Pluang's Aura AI — not financial advice
Fifth Third Bancorp (FITB) trades at $50.22, down 1.18% with bearish technical signals from moving averages. The stock shows solid fundamentals with a 22.36% net income margin and has beaten earnings expectations in two of the last three quarters. Recent news highlights the bank's innovation banking launch and Q3 guidance tracking at the high end of ranges post-Comerica conversion. Analyst consensus remains strongly positive with a $62.63 price target representing 25% upside potential.
FITB presents a compelling value opportunity with reasonable valuation multiples (P/E 16.91, P/B 1.41) and strong profitability metrics. Key risks include regulatory scrutiny of banking practices and integration challenges from the Comerica acquisition. The upcoming Q3 earnings report on October 19 will be crucial for validating the bank's growth trajectory and capital management strategy.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →